Suchen
Scinai Immunotherapeutics Ltd
SCNIZur Watchlist hinzufügen
1.910USD
+0.220+13.02%
Handelsschluss 09-22 16:00（ET）
1.29MMarktkapitalisierung
VerlustKGV TTM
Über Scinai Immunotherapeutics Ltd Unternehmen
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Scinai Immunotherapeutics Ltd Profil
BörsenkürzelSCNI
Name des UnternehmensScinai Immunotherapeutics Ltd
IPO-datumJun 07, 2007
CEOReichman (Amir)
Anzahl der mitarbeiter31
WertpapierartDepository Receipt
GeschäftsjahresendeJun 07
AddresseJerusalem Biopark, 2Nd Floor
StadtJERUSALEM
BörseNASDAQ OMX - NASDAQ BASIC
LandIsrael
Postleitzahl00000
Telefon97289302529
Websitehttps://www.scinai.com/
BörsenkürzelSCNI
IPO-datumJun 07, 2007
CEOReichman (Amir)
Führungskräfte von Scinai Immunotherapeutics Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Mark S. Germain
Mr. Mark S. Germain
Chairman of the Board
Chairman of the Board
120.00M
--
Mr. Mark S. Germain
Mr. Mark S. Germain
Chairman of the Board
Chairman of the Board
120.00M
--
Mr. Amir Reichman
Mr. Amir Reichman
Chief Executive Officer, Director
Chief Executive Officer, Director
1.95K
+58.59%
Mr. Amir Reichman
Mr. Amir Reichman
Chief Executive Officer, Director
Chief Executive Officer, Director
1.95K
+58.59%
Dr. Tamar Ben-Yedidia
Dr. Tamar Ben-Yedidia
Chief Scientific Officer
Chief Scientific Officer
1.35K
--
Dr. Tamar Ben-Yedidia
Dr. Tamar Ben-Yedidia
Chief Scientific Officer
Chief Scientific Officer
1.35K
--
Mr. Elad Mark
Mr. Elad Mark
Chief Operating Officer
Chief Operating Officer
487.00
+73.92%
Mr. Elad Mark
Mr. Elad Mark
Chief Operating Officer
Chief Operating Officer
487.00
+73.92%
Mr. Uri Ben-Or, CPA
Mr. Uri Ben-Or, CPA
Chief Financial Officer
Chief Financial Officer
118.00
+76.27%
Mr. Uri Ben-Or, CPA
Mr. Uri Ben-Or, CPA
Chief Financial Officer
Chief Financial Officer
118.00
+76.27%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Mark S. Germain
Mr. Mark S. Germain
Chairman of the Board
Chairman of the Board
120.00M
--
Mr. Mark S. Germain
Mr. Mark S. Germain
Chairman of the Board
Chairman of the Board
120.00M
--
Mr. Amir Reichman
Mr. Amir Reichman
Chief Executive Officer, Director
Chief Executive Officer, Director
1.95K
+58.59%
Mr. Amir Reichman
Mr. Amir Reichman
Chief Executive Officer, Director
Chief Executive Officer, Director
1.95K
+58.59%
Dr. Tamar Ben-Yedidia
Dr. Tamar Ben-Yedidia
Chief Scientific Officer
Chief Scientific Officer
1.35K
--
Dr. Tamar Ben-Yedidia
Dr. Tamar Ben-Yedidia
Chief Scientific Officer
Chief Scientific Officer
1.35K
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Scinai Immunotherapeutics Ltd?
Die fünf größten Anteilseigner von Scinai Immunotherapeutics Ltd sind: Mr. Mark S. Germain
Wie viele Institutionen halten Anteile an Scinai Immunotherapeutics Ltd (SCNI)?
Mit Stand vom 2026Q1 halten 23 Institutionen Anteile an Scinai Immunotherapeutics Ltd, mit einem Gesamtmarktwert von etwa 179.71K, was 5.08% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 33890.00 gestiegen.